Esperion Therapeutics | ESPR - Gross Profit On Sales

Stock Price
3.46
Daily Change
0.07 2.06%
Monthly
-2.54%
Yearly
84.04%
Q1 Forecast
2.70

Esperion Therapeutics reported $-29.52M in Gross Profit on Sales for its fiscal quarter ending in September of 2024.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Alnylam Pharmaceuticals USD 1.05B 418.14M Sep/2025
Amarin USD 22.21M 28.15M Sep/2025
Amgen USD 6.48B 307M Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Cipla INR 41.64B 6.31B Dec/2025
CSL USD 1.75B 2.53B Jun/2025
Cytokinetics USD 1.94M 64.83M Sep/2025
Daiichi Sankyo JPY 439.83B 95.05B Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
Geron USD 46.18M 1.66M Sep/2025
Grifols EUR 766.49M 39.74M Dec/2024
Halozyme Therapeutics USD 281.77M 2.41M Sep/2025
Heron Therapeutics USD 23.35M 1.6M Sep/2024
Ionis Pharmaceuticals USD 155M 293M Sep/2025
Merck USD 13.42B 431M Sep/2025
Minerva Neurosciences -4.27M 26.79M Dec/2024
Moderna USD 809M 791M Sep/2025
Nektar Therapeutics USD 13.75M 650K Jun/2024
Pfizer USD 3.54B 7.61B Sep/2025
PTC Therapeutics USD 187.69M 24.3M Sep/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Sanofi EUR 8.45B 1.31B Dec/2025
Sarepta Therapeutics USD 247.9M 209.96M Sep/2025
United Therapeutics USD 602.1M 108.9M Sep/2025
Vanda Pharmaceuticals USD 50.6M 5.5M Dec/2024